Atlas Trials

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

Clinical trial NCT06758726 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06758726
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
AML
Start date
2024-12-31
Primary completion
2026-10-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.